Chongqing Pharscin Pharmaceutical Co Ltd

Chongqing Pharscin Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 5.05, indicating that it has more than five times the current assets to cover its current liabilities. The company's liquidity is further supported by a debt-to-equity ratio of 0.0, suggesting that it is not reliant on debt financing and has a strong equity base. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the short term.

In terms of profitability, the company's return on equity (ROE) is 0.0042 and return on assets (ROA) is 0.0037, both of which are relatively low. These figures suggest that the company is not generating significant returns for its shareholders or efficiently utilizing its assets to generate profit. The gross profit margin is 52.45% (99,361,720 / 189,459,490), which is a positive sign, but the operating margin is only 5.06% (9,593,550 / 189,459,490), indicating that the company is facing high operating costs relative to its revenue.

The company's revenue is concentrated in a single geographic market, primarily China, as disclosed in its financial statements. There is no indication of significant international operations or diversified revenue streams, which could expose the company to higher regional economic and regulatory risks. The lack of segmental breakdown in the financial data also limits the ability to assess the performance of different product lines or therapeutic areas.

The company's growth trajectory appears to be modest, with no specific revenue growth rates provided in the available data. The operating cash flow of 64,757,980 CNY and capital expenditure of -7,647,750 CNY suggest that the company is generating positive cash flow but is not investing heavily in new projects or expansion. The absence of detailed guidance for the current or next fiscal year makes it difficult to assess the company's future growth prospects.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The low dilution risk is supported by the fact that the number of shares outstanding is the same for both basic and diluted shares, indicating no imminent threat of share dilution. However, the negative net cash position after subtracting total debt is a key flag that could impact the company's ability to meet short-term obligations. The company's capital structure is currently debt-free, which is a positive factor, but it may need to consider debt financing for future growth initiatives.

Recent events and filings do not provide specific details on the company's strategic initiatives or major developments. The lack of recent transcripts or significant announcements suggests that the company may not be in a high-growth or high-visibility phase. Investors should monitor the company's future filings for any changes in strategy, new product launches, or regulatory developments that could impact its performance.

Chongqing Pharscin Pharmaceutical Co Ltd (002907.SZ) has undergone a significant update to its corporate profile, with its economic sector now formally classified as Healthcare and its primary activity identified as Pharmaceuticals & Medical Research. This taxonomic clarification provides a clearer framework for understanding the company's operational focus within the broader market landscape. Alongside these classification updates, the company's risk assessment profile has been established with specific metrics. The dilution risk is currently rated as low, suggesting a stable capital structure regarding share issuance, while the liquidity risk is assessed at a medium level. These ratings offer initial insights into the financial stability and cash flow dynamics of the firm. The significance of these changes lies in the enhanced transparency of the company's fundamental characteristics. By defining its sector and activity, investors can better benchmark Chongqing Pharscin against peers in the Healthcare and Pharmaceuticals & Medical Research industries. The explicit risk ratings further aid in evaluating the potential volatility and financial health of the stock. Currently, the company shows no recorded analyst coverage, index membership, or disclosed top holders in the available data. This lack of external tracking metrics highlights the importance of the newly established internal risk and classification data for stakeholders seeking to analyze the company's position and potential. [doc:002907.sz-ha-financials]

The company generated CNY 90.8 million in free cash flow, demonstrating strong liquidity generation capabilities.

Cash conversion of 9.43 ranks as best-in-class among 859 pharmaceutical peers, indicating superior operational efficiency.

With a debt-to-equity ratio of 0.0, the firm sits above the 75th percentile for financial leverage safety.

Revenue grew 6.8% year-over-year to CNY 827.1 million, showing top-line expansion despite profit headwinds.

Low dilution and credit risk flags suggest a stable capital structure with minimal immediate financial distress signals.

Operating margin of 5.06% trails the 5.45% industry median, reflecting weaker core operational profitability.

A four-year net income CAGR of -8.2% indicates a persistent long-term decline in earnings power.